告別惱人過敏性鼻炎

[Guest]

http://news.pchome.com.tw/life/cna/20070311/index-20070311101950180027.html

告別惱人過敏性鼻炎 改善體質研究證實有效

溼冷的冬春之際，正是過敏性鼻炎好發時期，想擺脫不斷打噴嚏、流鼻水的惱人症狀，
民眾不妨從改善體質下手，中醫研究證實，若在過敏性鼻性發作的急性期及緩解期，分
別給予能調養氣虛體質的中藥湯劑，五個月就可有效改善症狀。

長庚醫院中醫醫院北院區中醫部主任楊賢鴻今天在第七十七屆國醫節慶祝大會暨學術研
討會上，發表這項「從實證醫學看中醫藥治療過敏性鼻炎」研究結果。

研究在過去九年間，共針對近三百名過敏性鼻炎患者進行實驗，結果發現，若分別在過
敏性鼻炎發作的頭三個月急性期，給予辛夷散、小青龍湯、香砂六君子湯等複方湯劑，
再在後二個月的緩解期，給予補中益氣湯，就可以改善症狀，且人人有效。

楊賢鴻說，免疫檢查顯示，透過服藥，患者原本體內高達六百以上的IG（過敏免疫球蛋
白）值，在急性期可以下降至四百左右，而在緩解期更可進一步恢復到一般人水準的兩
百以下，證實在中藥治療的免疫調節下，的確可以達到改善過敏體質、改善過敏症狀的
目的。

他指出，台灣過敏性鼻炎的主要過敏原來自塵（虫滿），因此，一年四季都是好發期，
是國內最常見的過敏性疾病，其次才是氣喘、異位性炎皮膚炎及蕁麻疹，尤其是季節轉
換的春、秋兩季，更是發作的高峰。

過敏性鼻炎患者在中醫觀點，屬於氣虛體質，楊賢鴻建議，想要斷根，除了透過補氣的
中藥調養外，平時更得遠離寒性的食物，包括白菜、荀子、香菇、西瓜、柳丁、柚子、
芒果等，特別是時下受歡迎的各式茶飲料，也是寒性的飲品，平時最好少碰為妙。

★★★★★

@南薑﹑ 黑棗﹑ 桂圓 及冰糖 加水燒成飲料， 很有效又好喝。

[Guest]

2007-03-14 16:52:57
http://news.pchome.com.tw/life/cna/20070320/index-20070320000824180024.html

中央研究院基因體研究中心特聘研究員張子文博士，成功研發出抗哮喘新藥anti-IgE藥
物Xolair，大幅減輕病患痛苦，二月下旬獲頒「美國過敏、哮喘與免疫學協會
（AAAAI）」醫學獎，這是這項世界級的殊榮獎項1947年設立以來第一次由華人獲
得。

張子文將於四月出刊的「Advances in Immunology（Vol.93）」期刊，發表長達六
十頁的詳盡研究報告「Anti-IgE Antibodies for the Treatment of IgE-Mediated
Allergic Diseases」，說明這項新藥研發是先從實驗室的小老鼠體內培養出IgE抗體物
質，取出後利用基因工程方法作人體化，修改成人體的抗體，在大型生物反 應槽利用動
物細胞生產。

他表示，在加入中央研究院基因體研究中心後，他更能夠專注在抗體工程於新藥開發的
研究，目前正致力於研發第二代的藥物。張子文二十年前因受過敏症之苦，開始研究抗
體工程，進而發明治療嚴重哮喘病症的新藥Xolair，三年前獲美國核准上市，最近剛獲
歐盟國家核准上市，對台灣超過一百萬的哮喘病患，也是個好消息。

在美國，衛生主管與保險支付機構根據經濟面合理考量，僅核准嚴重到氣管舒張器與類
固醇類藥物都無效時的嚴重哮喘病人可以使用，受益患者累計已達八萬人，去年一年就
創下四億六千萬美金的超高銷售金額。

擁有六千五百名會員的「美國過敏、哮喘與免疫學協會（AAAAI:American
Academy of Allergy Asthma,&Immunology）」，上個月二十五日在美國聖地牙
哥舉行年會，會中表彰張子文為2007年Honorary FellowAward得獎人。這個協會成
員是全球一百多個國家在過敏、哮喘與免疫方面的專業臨床醫師與學術研究人員，是這
個領域最大、最具影響力的組織，張子文所獲獎項是AAAAI最 高榮譽獎項，每年只頒給
一位在該領域有卓越成就與貢獻的會員，歷屆得獎者有多位諾貝爾獎等級的大師且多數
為美國國家科學院院士。

張子文表示，被AAAAI選為今年度受獎人，一方面是新藥治療很多嚴重的哮喘病人，也
釐清了IgE在哮喘和其他過敏疾病中發病的角色。他說，anti- IgE藥物被用在超過三十
個第二與第三期的臨床試驗，針對不同的免疫類疾病作臨床試驗，涵蓋哮喘、過敏性鼻
炎、食物、皮膚方面的過敏等極為普遍的病症。

他指出，越是先進國家，免疫型疾病的狀況越嚴重。美國、西歐越來越多孩童對含花生
物質有強烈的過敏反應。目前全球有百分之十五的人正受過敏所苦，也造成家庭和社會
經濟的負擔。

Genomics Research Center
Dr. Tse Wen Chang, Distinguished Research Fellow of Genomics
Research Center, was recognized by the "American Academy of Allergy,
Asthma & Immunology", a.k.a. AAAAI on February 25 in its 2007 annual
meeting by granting an AAAAI 2007 Honorary Fellow Award. AAAAI grants
one such award to one recipient yearly since 1947, and Dr. Chang is the
first Chinese who has won such honor.

Of the few Chinese scientists who succeed in academic and
entrepreneurial aspects in regards to new drug development, Dr. Chang
has a good insight in making genetically engineered antibodies. 20 years
ago, partly because he himself suffered from severe hey-fever, he
investigated the immune mechanisms of allergic responses. His invention
later turned into many valuable patents and a drug Xolair, which has been
approved for asthma treatment in the United States, European Union, and
many other countries.

Although this new drug has generated US$ 460 million sales in 2006
in the US alone, Dr. Chang thinks that his recognition by AAAAI is partly
because the drug has been used to relieve the suffering of many patients
with severe asthma and partly because the drug has clarified role of IgE
in the pathogenesis of asthma and other allergic diseases. In fact, the
anti-IgE drug has been investigated in more than 30 phase II and phase
III clinical trials on various allergic indications, including asthma, allergic
rhinitis, anaphylactic reactions to peanuts, atopic dermatitis, and others,
which affect large populations of patients.

Chang said that allergic diseases are more prevalent in economically
advanced countries. For example, in the United States and western
European countries, many children are allergic to peanuts, and in Taiwan,
living in closed shelters has led to the exposure of high concentrations of
airborne dust mites and increased asthmatic cases, especially among
young children. Allergic diseases cause strains in families and huge
healthcare costs. Xolair is currently prescribed for treating
moderate-to-severe cases of asthma that cannot be controlled by
bronchial dilators and corticosteroids. More than 80,000 patients have
benefited from Xolair.

The creation of Xolair was started from anti-IgE antibodies prepared
from lab mice. Chang successfully modified it into human antibodies with
genetic engineering methodologies. The anti-IgE drug is produced by
animal cells cultured in large bioreactor tanks. According to Chang, since
he joined the Genomics Research Center in 2006, he has been stepping
up efforts on developing novel antibody-based therapeutics. The second
generations of anti-IgE drugs are part of his research endeavors.

Dr. Tse Wen Chang has written up an updated review summarizing
the development of anti-IgE approach. The article titled “Anti-IgE
Antibodies for the Treatment of IgE-Mediated Allergic Diseases “will be
published in the April issue of "Advances In Immunology" vol. 93.

About AAAAI
The "American Academy of Allergy, Asthma & Immunology", a.k.a.
AAAAI, has over 6500 members, among them more than 1000 fellows, of
mostly practicing doctors and academic clinical researchers. It is the
largest international professional society in the field of allergy, asthma,
and immunology. AAAAI grants one Honorary Fellow Award each year in
its annual meetings.

db1.sinica.edu.tw/~textdb/test/gatenews/